NeuroVigil

NeuroVigil operates at the intersection of neurotechnology, medical devices, neuroscience, and clinical research. Its stated differentiation is the combination of non-invasive brain-monitoring hardware—particularly the portable iBrain—with machine-learning analysis intended to identify brain-signal biomarkers. The company describes applications ranging from neurological-condition research to assessing intent in people who cannot communicate. The listed peer candidates are duplicate entries for NeuroVigil itself, so there is no defensible basis here to name or rank specific company competitors. Its competitive context is therefore better described by category: EEG and neurodiagnostic device makers, digital-health monitoring products, and research tools used in neurology and pharmaceutical studies. TIME’s 2025 Best Inventions recognition provides a visibility signal for iBrain, but is not evidence of market share. NeuroVigil’s small reported employee range of 1–10 and lack of disclosed financing since 2015 also distinguish its scale from larger, better-capitalized medical-device businesses. Assessing its market position more precisely would require comparable product, regulatory, clinical, and commercial evidence.

NeuroVigil was founded on February 5, 2007, and its recorded financing history indicates a long development period: a $250,000 Seed round dated May 1, 2011, followed by a Series B dated May 1, 2015, with no Series B amount disclosed. A separate financial signal names a Series A but provides neither an amount nor a date, so the precise sequence and total capital raised are uncertain. The next clear product inflection point is the April 2024 U.S. launch of iBrain, a portable non-invasive brain monitor. TIME’s October 2025 Best Inventions recognition added visibility roughly 18 months later. This timeline suggests a company moving from extended technology development toward a more visible product phase, rather than demonstrating a recently accelerated financing or hiring cycle. The reported employee band is 1–10, and the company says it is committed to growing organically; no hiring expansion or recent layoffs are indicated. Overall, the trajectory shows meaningful product and recognition milestones, alongside limited evidence about commercial expansion.